Abstract
68P Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have